Dyadic International, Inc. announced its financial results for the second quarter of 2025, reporting a total revenue of $967,000. This represents a significant increase of 150.5% compared to $386,000 for the same period in the prior year.
The revenue growth was primarily driven by a $250,000 milestone payment from the Inzymes Agreement and grant revenue from the Gates Foundation and CEPI. The net loss for the second quarter of 2025 decreased to $1,794,000, or $(0.06) per share, from $2,045,000, or $(0.07) per share, in Q2 2024.
General and administrative expenses decreased by 10.6% to $1,437,000, reflecting disciplined cost management. As of June 30, 2025, the company's cash, cash equivalents, restricted cash, and short-term investment securities totaled approximately $7.3 million, further bolstered by $5.3 million in net proceeds from a public offering that closed on August 1, 2025. The company anticipates upcoming launches of DNase I and recombinant human albumin through its partnership with Proliant Health and Biologics.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.